Nachrichten und Videos - BLUEBIRD BIO INC.

bluebird bio, Inc. (NASDAQ: BLUE) today announced that October 19, 2021 has been set as the record date for the dividend of shares of common stock of 2seventy to be distributed to bluebird stockholders in order to effect the separation of bluebird bio and 2seventy bio, Inc. into two independent, publicly traded companies. Each bluebird bio stockholder of record as of the close of business on October 19, 2021 will receive, on the distribution date, one share of 2seventy common stock for every...

bluebird bio, Inc. (NASDAQ: BLUE) today announced the filing by 2seventy bio of an updated Form 10 Registration Statement with the U.S. Securities and Exchange Commission (SEC). This Form 10 reflects bluebird bio’s plans for a tax-free spin-off of its oncology programs and portfolio into 2seventy bio as a publicly traded company. The spin-off is on track to be completed by early November 2021. bluebird bio also announced the appointment of Najoh Tita-Reid and Sarah Glickman to the bluebird bio...

bluebird bio, Inc . (Nasdaq: BLUE) today announced it has completed the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for betibeglogene autotemcel (beti-cel) gene therapy in adult, adolescent and pediatric patients with β-thalassemia who require regular red blood cell (RBC) transfusions, across all genotypes. The FDA previously granted beti-cel Orphan Drug status and Breakthrough Therapy designation for the treatment of...

2seventy bio, the planned oncology spin-off of bluebird bio (NASDAQ: BLUE) announced today that it will host a series of investor events to share further detail on its research pipeline and strategy. Session One: An Introduction to 2seventy’s Pipeline; focus on AML [DARIC33] and Next-Gen Multiple Myeloma Strategy September 21, 2021, 11:00am-12:00pm ET Session Two: Focus on bNHL [bbT369] and Solid Tumor Strategy September 22, 2021, 1:00-2:00pm ET To access the live webcasts and dial-in...

bluebird bio, Inc. (NASDAQ: BLUE) announced today that it has entered into an agreement for a $75 million private placement of common stock and common stock equivalents with a healthcare investment fund selected as part of a competitive process. Proceeds from the financing will support ongoing R&D and commercialization investments for bluebird bio and for 2seventy bio, which plan to launch as independent companies in October 2021. The closing of the private placement is expected to occur in...

bluebird bio, Inc. (NASDAQ: BLUE) today announced key management and board appointments in advance of the company’s planned separation, targeted for mid-October, 2021. The company also outlined plans for investor events and participation in investor conferences leading up to the separation. “As we approach separation, we are focused on ensuring that both bluebird bio and 2seventy bio have strong management teams and boards in place to carry each company through its next phase,” said Nick...

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into bluebird bio, Inc. (NasdaqGS: BLUE). In May 2020, the Company announced its plans to submit an application to the U.S. Food and Drug Administration (“FDA”) for its product, LentiGlobin, in the second half of 2021. Then, on November 4, 2020, the Company disclosed that, due to the FDA requiring the Company to...

bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the second quarter ended June 30, 2021 and provided operational updates, including the announcement that the U.S. Food and Drug Administration (FDA) placed a clinical hold on clinical studies of elivaldogene autotemcel (eli-cel, Lenti-D™) gene therapy (licensed as SKYSONA™ in Europe) for cerebral adrenoleukodystrophy (CALD). “I’m tremendously proud of what bluebird has accomplished this quarter...

bluebird bio, Inc. (NASDAQ: BLUE) today announced that the Company will report financial results for the second quarter ended June 30, 2021 on Monday, August 9, 2021 and host a conference call to discuss the quarterly update on Monday, August 9, 2021 at 8 a.m. ET. Investors may listen to the call by dialing (844) 825-4408 from locations in the United States or +1 (315) 625-3227 from outside the United States. Please refer to conference ID number 9698691. Additionally, members of the management...

bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company’s Board of Directors approved inducement grants of stock options to purchase a total of 85,000 shares of common stock and 50,000 restricted stock units (“RSUs”) to a newly hired employee with a grant date of August 2, 2021 (the “Inducement Grants”). The Inducement Grants are subject to the terms and conditions of award agreements covering the grants and the Company’s 2021 Inducement Plan....

National Resilience, Inc. (Resilience) and bluebird bio, Inc. (NASDAQ: BLUE), today announced a strategic alliance aimed to accelerate the early research, development and delivery of cell therapies. As part of the agreement, Resilience will acquire bluebird’s Research Triangle (bRT) manufacturing facility located in North Carolina and retain all of the more than 100 highly skilled technical staff and administrators currently employed at the site. Resilience will continue to support vector...

BLUEBIRD BIO INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of bluebird bio, Inc. - BLUE PR Newswire NEW ORLEANS, La., July 23, 2021 NEW ORLEANS, La. , July 23, 2021 /PRNewswire/ -- Former Attorney General of Louisiana , Charles C. Foti, Jr., Esq. , a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into bluebird bio, Inc. (NasdaqGS: BLUE). In May 2020 , the...

bluebird bio, Inc . (Nasdaq: BLUE) today announced that the European Commission (EC) has granted marketing authorization of SKYSONA™ (elivaldogene autotemcel, Lenti-D™), a one-time gene therapy for the treatment of early cerebral adrenoleukodystrophy (CALD) in patients less than 18 years of age with an ABCD1 genetic mutation, and for whom a human leukocyte antigen (HLA)-matched sibling hematopoietic (blood) stem cell (HSC) donor is not available. SKYSONA is the first one-time gene therapy...

bluebird bio, Inc . (Nasdaq: BLUE) today announced that the European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has concluded based on the review of all available data that the benefit-risk balance of medicinal products containing ZYNTEGLO™ (betibeglogene autotemcel gene therapy) remains favorable. As of today, bluebird bio has informed the EMA that the company is lifting the voluntary marketing suspension. “Patient safety remains our top priority. To this...

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into bluebird bio, Inc. (NasdaqGS: BLUE). In May 2020, the Company announced its plans to submit an application to the U.S. Food and Drug Administration (“FDA”) for its product, LentiGlobin, in the second half of 2021. Then, on November 4, 2020, the Company disclosed that, due to the FDA requiring the Company to...

bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Goldman Sachs 42 nd Annual Global Healthcare Conference, Tuesday, June 8, at 8:50 a.m. ET. To access the live webcast of bluebird bio’s presentation, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com . A replay of the webcast will be available on the bluebird bio website for 90 days...

bluebird bio, Inc . (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical holds on the Phase 1/2 HGB-206 and Phase 3 HGB-210 studies of LentiGlobin for sickle cell disease (SCD) gene therapy (bb1111) for adult and pediatric patients with SCD, and the Phase 3 Northstar-2 (HGB-207) and Northstar-3 (HGB-212) studies of betibeglogene autotemcel gene therapy (beti-cel; licensed as ZYNTEGLO ™ in the EU and the UK) for adult, adolescent and pediatric...

bluebird bio, Inc . (Nasdaq: BLUE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization for SKYSONA™ (elivaldogene autotemcel, Lenti-D™), a one-time gene therapy for the treatment of early cerebral adrenoleukodystrophy (CALD) in patients less than 18 years of age with an ABCD1 genetic mutation, and for whom a human leukocyte antigen (HLA)-matched sibling...

bluebird bio, Inc . (Nasdaq: BLUE) announced today that data from its gene therapy programs for transfusion-dependent β-thalassemia (TDT) and sickle cell disease (SCD) and its cell therapy program for relapsed or refractory multiple myeloma (R/RMM) will be presented during EHA2021 Virtual, the 26 th Annual Congress of the European Hematology Association, taking place June 9-17, 2021. bluebird bio will present data from its ongoing clinical studies of betibeglogene autotemcel (beti-cel),...

bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the first quarter ended March 31, 2021 and shared recent operational progress. “Undoubtedly the highlight of last quarter at bluebird was the approval of Abecma, the first and only CAR T therapy approved for the treatment of relapsed or refractory multiple myeloma,” said Nick Leschly, chief bluebird. “We and our colleagues at BMS are now full speed ahead and on track to begin treating patients...